Il sistema RANKL/RANK, osteoprotegerina e osteopontina in una coorte di soggetti affetti da poliartrite cronica. Studio preliminare

Translated title of the contribution: RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report

Giovanna Minenna, Simona D'Amore, Piera Maggiolini, Pasquale Scagliusi, Massimo D'Amore

Research output: Contribution to journalArticle


Recently, receptor activator of nuclear factor-kB ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin (OPG), have been identified as paracrine mediator of bone functions. The balance of RANKL/RANK and OPG is critical for osteoclastogenesis modulation and physiological bone remodeling. Osteopontin (OPN) is an extracellular glycosylate bone phosphoprotein and acts both as chemokine and cytochine. It is produced by osteoclast, macrophages, T cells, hematopoietic cells and vascular smooth muscle cells. It is present particularly at high concentration in the lamina limitans and cement line, suggesting its role in the initiation and termination of the bone turnover. Chronic arthritis are a group of rheumatic patologies characterized by periodical continuous or desultory use of corticosteroides. The main aims of this study are to valuate OPG, RANKL and OPN serum concentrations in patients affected by chronic arthritis and to compare the above results with those ones obtained by young healthy population. OPG, RANKL and OPN serum concentration has been measured by ELISA method both in 40 patients affected by chronic arthritis then in young healthy population of 81 subjects. The differences between the two considered groups have been analyzed using unpaired T-Student. The difference between the two groups is significant for considered variables: OPG: t=-6,54, p

Original languageItalian
Pages (from-to)431-432
Number of pages2
JournalRecenti Progressi in Medicina
Issue number9
Publication statusPublished - Sep 2005


ASJC Scopus subject areas

  • Medicine(all)

Cite this